UNSPSC 85815231: Introduction of oxazolidinones into respiratory tract, via natural or artificial opening

This classification denotes the group of activities that yields a administrative intervention or procedure to introduction of oxazolidinones into respiratory tract, via natural or artificial opening. This administrative intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 3E0F728

UNSPSC 85815231 (Introduction of oxazolidinones into respiratory tract, via natural or artificial opening) is a Commodity code that shows minimal alignment with actual state and local procurement activity. The recent opportunities block contains no contracts for the pharmaceutical administration or pulmonary delivery of oxazolidinone agents that the code nominally describes. Instead, the recent state and local solicitations tagged under this code cover virtual urgent care, general medical services, nursing home operations, cancer screening, occupational health, EMS staffing, employee health clinics, psychological evaluations, opioid treatment programs, naloxone distribution, wellness services, and recovery audit services—none of which involve oxazolidinone respiratory therapy or chemotherapy. This mismatch suggests either inconsistent code tagging in the source system or that the code as applied does not reflect what state and local buyers are actually procuring under the ostensible classification.

The issuing bodies across the recent postings include state health authorities (Nevada, Texas, Colorado, Illinois Secretary of State, New Jersey), county agencies (San Mateo, DeKalb, Brevard, Santa Clara, Seminole, Sarasota, Cobb, Los Alamos, Forsyth, Rockland, Washington, Jackson), municipalities (Phoenix, Atlanta, Ocala, Boulder County Sheriff, Fairfax), public health departments (Solano), special districts (Events DC, Sourcewell cooperative, H-GAC), school districts (Parkway), and transit-adjacent departments, with significant clustering around behavioral health, occupational medicine, emergency medical services, and recovery programs funded by opioid settlement monies. Geographic spread spans California, Colorado, Florida, Georgia, Illinois, Kansas, Michigan, Minnesota, Missouri, Nevada, New Jersey, New York, North Carolina, Oregon, Texas, and Virginia, with no dominant regional concentration. The code shows substantial recent activity but none of it is medically relevant to oxazolidinone therapeutics; state and local procurement professionals pursuing opportunities under this code should verify correct UNSPSC tagging or seek clarification from the issuing body before investing business development effort.